Jasper Therapeutics Inc
NASDAQ:JSPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
US |
|
W
|
Woodside Petroleum Ltd
XBER:WOPA
|
AU |
|
P
|
PNC Process Systems Co Ltd
SSE:603690
|
CN |
|
Mapfre SA
LSE:0NQ2
|
ES |
|
North West Company Inc
TSX:NWC
|
CA |
|
D
|
DaedongGear
KOSDAQ:008830
|
KR |
|
Z
|
Zhongnanhong Culture Group Co Ltd
SZSE:002445
|
CN |
|
H
|
Hank Payments Corp
XTSX:HANK
|
CA |
|
361 Degrees International Ltd
HKEX:1361
|
CN |
|
P
|
Pubang Landscape Architecture Co Ltd
SZSE:002663
|
CN |
|
Realcan Pharmaceutical Group Co Ltd
SZSE:002589
|
CN |
|
R
|
Rizzo Group AB
STO:RIZZO B
|
SE |
|
Shenzhen Huijie Group Co Ltd
SZSE:002763
|
CN |
Jasper Therapeutics Inc
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.
